Study: Capecitabine Combination Therapy Reduces Early Breast Cancer Recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34 percent reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.
Yahoo! Finance